XERESE Drug Patent Profile
✉ Email this page to a colleague
When do Xerese patents expire, and what generic alternatives are available?
Xerese is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in XERESE is acyclovir; hydrocortisone. There are fifty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acyclovir; hydrocortisone profile page.
Summary for XERESE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Clinical Trials: | 1 |
| Patent Applications: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for XERESE |
| What excipients (inactive ingredients) are in XERESE? | XERESE excipients list |
| DailyMed Link: | XERESE at DailyMed |
Recent Clinical Trials for XERESE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Meda Pharmaceuticals | Phase 3 |
| TKL Research, Inc. | Phase 3 |
Pharmacology for XERESE
Anatomical Therapeutic Chemical (ATC) Classes for XERESE
US Patents and Regulatory Information for XERESE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | XERESE | acyclovir; hydrocortisone | CREAM;TOPICAL | 022436-001 | Jul 31, 2009 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XERESE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | XERESE | acyclovir; hydrocortisone | CREAM;TOPICAL | 022436-001 | Jul 31, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bausch | XERESE | acyclovir; hydrocortisone | CREAM;TOPICAL | 022436-001 | Jul 31, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bausch | XERESE | acyclovir; hydrocortisone | CREAM;TOPICAL | 022436-001 | Jul 31, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XERESE
See the table below for patents covering XERESE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Yugoslavia | 49477 | ⤷ Try a Trial | |
| South Korea | 100431042 | ⤷ Try a Trial | |
| Spain | 2214528 | ⤷ Try a Trial | |
| Croatia | P960034 | NOVEL PHARMACEUTICAL COMBINATION | ⤷ Try a Trial |
| Austria | 238796 | ⤷ Try a Trial | |
| New Zealand | 301407 | TOPICAL COMPOSITION COMPRISING AN ANTIINFLAMMATORY GLUCOCORTICOID AND AN ANTIVIRAL SUCH AS ACYCLOVIR | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XERESE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0809498 | 10C0038 | France | ⤷ Try a Trial | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| 0809498 | CA 2010 00009 | Denmark | ⤷ Try a Trial | |
| 0809498 | SPC/GB10/012 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
